About This Treatment Guide

Article

About This Treatment Guide

The Oncology Group of CMPMedica, publisher of ONCOLOGY and Oncology NEWS International, and the website, cancernetwork.com, is pleased to present Cancer Management: A Multidisciplinary Approach, 11th edition. Cancer Management: A Multidisciplinary Approach is designed to present important clinical information concisely, uniformly, and logically, emphasizing the natural history of the malignancy, screening and diagnosis, staging and prognosis, and treatment.

The fundamental principle behind this comprehensive treatment guide is the importance of a truly integrated, multidisciplinary approach to the management of the patient with cancer. Accordingly, the discussion of each disease site combines the perspectives of medical oncology, surgical oncology, and radiation oncology, as appropriate. Further, each of the book’s medical editors represent a particular discipline.

The Oncology Group would like to thank the contributors and all involved in the development and production of this important handbook. In particular, we thank the book’s principal editors:

 

Richard Pazdur, MD

(Medical Oncology)
US Food and Drug Administration

Lawrence D. Wagman, MD

(Surgical Oncology)
Center for Cancer Prevention and Treatment, St. Joseph Hospital

Kevin A. Camphausen, MD

(Radiation Oncology)
National Cancer Institute

William J. Hoskins, MD

(Gynecologic Oncology)
Memorial Sloan-Kettering Cancer Center


We also thank the staff of The Oncology Group and in particular wish to recognize the efforts of Angela Cibuls and Susan Reckling.

This 11th edition has been produced in an effort to keep pace with the rapidly changing field of oncology. Be sure to visit www.cancernetwork.com, where the full text of this edition will be made available online, with important updates as appropriate.

Please let us know how you use this book, and how we can make it even more valuable. We look forward to hearing from you.

Sincerely,

Cara H. Glynn
Beth Scholz

 

 

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
Related Content